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Several studies on aetiologically unrelated catabolic conditions
suggest that the massive loss of skeletal muscle mass (cachexia) is
associated with a decrease in the intracellular glutathione (GSH)
level in the muscle tissue. Decreased GSH levels and increased
glutathione disulphide/glutathione (GSSG/GSH) ratios have been
observed in skeletal muscle of weight-losing tumour-bearing mice
(Hack et al, 1996a) and rhesus monkeys infected with the simian
immunodeficiency virus (SIV) (Groß et al, 1996), i.e. the best exper-
imental animal model of AIDS. Unless cysteine or glycine or the
corresponding biosynthetic enzymes become limiting, the GSH level
is determined by the glutamate level, because GSH competes with
glutamate for the glutamate-binding site of the g-glutamyl-cysteine
synthetase in the first and rate-limiting step of GSH biosynthesis
(Richman and Meister, 1975). The skeletal muscle tissue of tumour-
bearing mice and SIV-infected monkeys showed indeed a decreased
intracellular glutamate level (Groß et al, 1996; Hack et al, 1996a).
Several lines of evidence suggest that the decrease in the intra-
muscular glutamate level results from a decreased glutamate trans-
port activity across the plasma membrane. First, studies of amino
acid exchange rates across the lower extremities revealed that the
relative glutamate uptake of cancer patients is significantly
decreased (Hack et al, 1996b). Secondly, the decrease in the
muscular glutamate level of tumour-bearing mice and SIV-infected
rhesus macaques was found to be associated with a strong increase
in the plasma glutamate level (Groß et al, 1996, Hack et al, 1996a).
And finally, increased post-absorptive venous plasma glutamate
levels have been found in all catabolic conditions tested so far
including malignancies (Brennan, 1977; Dröge et al, 1988a, 1988b;
Pisters and Pearlstone, 1993), HIV/SIV infection (Eck et al, 1989,
1991), sepsis (Siegel et al, 1979), non-insulin-dependent diabetes
mellitus (Hack et al, 1996a), amyotrophic lateral sclerosis
(Plaitakis and Caroscio, 1987) and old age (Hack et al, 1996b).
Even in healthy human subjects, it was observed that episodes with
elevated plasma glutamate levels were significantly correlated with
a decrease in body cell mass (Kinscherf et al, 1996). A study of
lung cancer patients revealed that plasma glutamate levels were
significantly correlated with mortality (Eck et al, 1989). The
impairment of the glutamate uptake appears to be a relatively early
event in the development of cachectic processes, because increased
plasma glutamate levels are found already in the very early stages
of HIV and SIV infection (Eck et al, 1991; Groß et al, 1996; Hack
et al, 1997), and a decrease in glutamate uptake was found already
in well nourished cancer patients (Hack et al, 1996b).
Because glutamate is transported into muscle cells mainly by a
Na+-dependent membrane transport system (Horn 1989; Low et al,
1994; McGivan and Pastor-Anglada, 1994), and in view of the link
between Na+ gradient and intracellular pH via the Na+/H+ antiport,
we consider the working hypothesis that decreased glutamate
transport activity may be an indirect consequence of abnormally
high glycolytic activity. An increased glycolytic activity has been
reported to occur quite regularly and relatively early in malignan-
cies, burn injuries and sepsis (Wilmore and Aulick, 1978; Roth et
al, 1982; Striebel et al, 1986; Shaw and Wolfe, 1987; Tayek,
1992). A high glycolytic activity and lactate production is an indi-
cation that the capacity of the mitochondrial energy metabolism is
too weak to meet the cellular demand for ATP.
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Summary Abnormally low intramuscular glutamate and glutathione (GSH) levels and/or a decreased muscular uptake of glutamate by the
skeletal muscle tissue have previously been found in malignant diseases and simian immunodeficiency virus (SIV) infection and may contribute
to the development of cachexia. We tested the hypothesis that an impaired mitochondrial energy metabolism may compromise the Na+-
dependent glutamate transport. A randomized double-blind clinical trial was designed to study the effects of L-carnitine, i.e. an agent known to
enhance mitochondrial integrity and function, on the glutamate transport and plasma glutamate level of cancer patients. The effect of carnitine
on the intramuscular glutamate and GSH levels was examined in complementary experiments with tumour-bearing mice. In the mice, L-
carnitine treatment ameliorated indeed the tumour-induced decrease in muscular glutamate and GSH levels and the increase in plasma
glutamate levels. The carnitine-treated group in the randomized clinical study showed also a significant decrease in the plasma glutamate
levels but only a moderate and statistically not significant increase in the relative glutamate uptake in the lower extremities. Further studies may
be warranted to determine the effect of L-carnitine on the intramuscular GSH levels in cancer patients. © 2000 Cancer Research Campaign
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metabolism because it serves as a carrier for fatty acids across the
inner mitochondrial membrane (Bremer, 1983). In several studies,
carnitine or acetyl-carnitine were found to enhance mitochondrial
integrity and function (Nikula, 1985; McFalls et al, 1986; Hagen et
al, 1998). This effect is attributed mainly to the transfer of inner
mitochondrial acyl-moieties (Rebouche and Paulson, 1986). Two
investigations on cancer patients revealed that the patients under
study had an abnormally high renal clearance of carnitine (Dodson
et al, 1989) and a significantly decreased carnitine level in the
skeletal muscle tissue respectively (Rössle et al, 1989). Moreover,
treatment of tumour-bearing rats was shown to ameliorate the
tumour-induced increase in plasma triglycerides (Winter et al,
1995). We, therefore, studied the hypothesis that administration of
L-carnitine to cancer patients and tumour-bearing mice may
ameliorate the decrease in glutamate uptake, intracellular gluta-
mate and GSH levels in the skeletal muscle tissue respectively.
PATIENTS, MATERIALS AND METHODS
Randomized double-blind clinical trial
Well nourished patients with carcinoma of the stomach, the colon,
the liver, the pancreas, the kidney or the lung were eligible.
Patients younger than 20 or older than 75 years, patients who were
undergoing surgery within 3 months before recruitment and
patients who had already received chemotherapy or radiation
therapy were not eligible. Also excluded were patients with
diabetes mellitus or other endocrinological diseases, multiple scle-
rosis, serum creatinine > 2 mg dl–1, cardio-respiratory insuffi-
ciency, alcohol or drug abuse, anaemia, or pregnant women.
Clinical laboratory data including the electrolytes, glucose, total
bilirubin, creatinine, ALT, cholesterol and triglycerides were in the
normal range. Twenty-eight patients were recruited and randomly
assigned to the L-carnitine (n = 14) and placebo (n = 14) groups.
Randomization was performed by the biostatistics unit of the
German Cancer Research Center (LE). The study was approved by
the ethics committee of the Medical Faculty of the University of
Heidelberg/Mannheim and was conducted according to the GCP-
ICH/GLP guidelines and to the principles of the declaration of
Helsinki. All patients gave their informed consent.
The patients received a daily oral dose of 2 g L-carnitine or
placebo dissolved in fruit juice for 5 consecutive days and were
examined twice, i.e. on the first day of treatment and 5 days after
the start of treatment. The placebo contained propyl-4-hydroxy
benzoate, sorbitol and lemon flavouring. The estimated dietary carni-
tine intake was approximately 50 mg day–1. Blood samples were
taken in the post-absorptive state from the femoral artery and vein.
Additional blood samples were taken from the cubital vein for
routine clinical parameters. Carnitine and carnitine-esters were deter-
mined as described by McGarry and Foster (1976). Plasma amino
acid concentrations, plasma glucose, lactate and ketone bodies were
determined as described by Hack et al (1996b). Prospectively defined
primary outcome measure was the glutamate exchange rate. Because
the glutamate uptake was previously shown to depend strongly on
the arterial glutamate concentration, we expressed the data as
‘relative glutamate uptake’ (i.e. the ratio of glutamate uptake/arterial
glutamate level) as defined by Hack et al (1996b). Secondary
outcome measures were the venous plasma glutamate level and the
exchange rates of glutamine and glucose. Plasma amino acid and
whole blood glucose exchange rates were determined as described
(Hack et al, 1996b).
The relative changes of the outcome parameters of the two
different treatment groups were compared by the Wilcoxon rank-
sum-test. P-values <0.05 were regarded as statistically significant.
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Table 1 Baseline characteristicsa of the patients in the randomized double-blind trial
L- -carnitine (n = 14) Placebo (n = 14)
Male/female 10/4 8/6
Age (years)b 64.0±9.9 64.3±9.3
Percentage of optimimal body weightb 116.7±16.6 105.4±10.8
Body cell mass (BCM) indexb,c 9.2±2.3 (10.2/6.8) 8.3±1.7 (9.3/7.1)
(male/female) (kg m–2)
Tumour type
Gastrointestinal (n)1 0 1 0
Renal cancer (n)1 2
Others (n)3 2
Free carnitine
Arterial mM 30.3±2.6 32.1±2.7 (30.1±1.8)d
Venous mM 34.2±2.2 33.2±2.7 (31.1±1.8)d
Acyl-carnitinec
Arterial mM 16.2±3.3 9.7±1.7 (10.1±0.9)d
Venous mM 14.7±2.2 11.4±1.4 (10.2 ± 1.3)d
a Electrolytes and routine liver and kidney parameters were in the normal range. bMean ± standard error of the mean (s.e.m.). cBCM height–2; mean of healthy
controls (m/f): 10.8 ± 1.8 (11.9/8.8) kg m–2. dMean values ± s.e.m. of a healthy age-matched control population (n = 14) is given in brackets.
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Figure 1 Effect of L-carnitine or placebo on the relative change in plasma
glutamate, glucose and glutamine. The data show the median (strong line)
and the mean (thin line) of the plasma concentrations at terminal examination
expressed as % of the corresponding individual baseline values. The box plot
describes, in addition, the first (25%) and third (75%) quartile of the
distribution. The P-value is given for the difference between the L-carnitine
group (C) and the placebo group (PL). The dashed line indicates no change
(100%)Arithmetic means and standard errors of the mean (s.e.m.) were
used as descriptive statistics.
L-carnitine treatment of tumour-bearing mice
Female C57BL/6 mice were obtained from the Central Animal
Laboratories of the German Cancer Research Center (DKFZ),
Heidelberg. The mice were fed ad libitum with a standard diet
(Altromin) and were usually 10–16 weeks old at the start of the
experiment. Altromin containes 3% ‘fishprotein’ (Dr Madry,
Altromin, personal communication). ‘Fishprotein’, in turn, was
reported to contain 1.5 mmol of L-carnitine g–1 wet weight
(http://galaxy.com/galaxy/Community/Health/Diet/carnitine/food.
htm). The MCA-105 fibrosarcoma was originally induced in a
C57BL/6 mouse by intramuscular injection of methylcholanthrene
(Fox et al, 1990). In the present study, the mice received 3 ´ 106
tumour cells in 0.1 ml HBSS subcutaneously (day 0) and daily
intraperitoneal injections of 0.4 ml HBSS containing either 0.0,
0.04, 0.2, 1.0 or 5.0 mg L-carnitine on days 11–15 and 18–22. As a
rule, the tumour was barely palpable on day 11 and had a diameter
of about 1 cm on day 22. The mice were not cachectic. L-carnitine
had no significant effect on the tumour size.
The mice were bled from the tail vein. Blood was collected in
heparinized tubes, and the plasma amino acid concentrations were
determined with an amino acid analyser (Biotronic LC 3000) as
described (Hack et al, 1996a).
M. gastrocnemius and M. vastus lateralis were prepared sepa-
rately and further dissected into a red section (muscle type 2A) and
a white section (type 2B). The white sections were stored at
–80°C, and pulverized in liquid nitrogen. Samples of liver or
muscle powder were transferred into 0.4 ml 2.5% sulphosalicylic
acid, subjected to sonification and finally kept on ice for at least
20 min. The mixture was centrifuged for 10 min at 12 000 g, and
the supernatants were used for the determination of amino acids
(Biotronic LC 3000 amino acid analyser), total glutathione
according to Tietze (1969), and glutathione disulphide according
to Griffith (1980). The corresponding pellet was used to determine
the protein content by the procedure of Peterson (1977).
RESULTS
A placebo-controlled double-blind trial on the effects of
L-carnitine
The baseline characteristics of the two treatment groups were not
significantly different (Table 1), and there was no significant
change in the plasma levels of carnitine or carnitine esters during
the treatment (not shown). The glutamate exchange rates of the L-
carnitine and placebo groups at baseline examination were expect-
edly relatively low (i.e. 48.3 ± 8.7 and 39.2 ± 7.7 nmol–1 min–1
100 ml–1) (compare Hack et al, 1996b). The carnitine-treated group
showed, on average, a significant decrease in the venous plasma
glutamate level but only a moderate and statistically not significant
increase in the relative glutamate uptake in the lower extremities
(Figure 1 and 2). In addition, L-carnitine treatment increased the
release of BCAA in comparison with the placebo group but had no
detectable effect on the plasma glutamine or glucose levels (Figure
1) and on the muscular glucose uptake (Figure 2).
The treatment was well tolerated. No serious side-effects or
subjective changes have been reported.
Effects of L-carnitine on the glutamate and GSH levels
in tumour-bearing mice
Because the clinical study did not allow us to determine the
resulting changes in the intracellular GSH and glutamate levels of
the skeletal muscle tissue, we also studied the effect of carnitine on
tumour-bearing mice.
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Figure 2 Effect of L-carnitine or placebo on the exchange rates of plasma
glutamate, glucose and branched-chain amino acids. The data show the
mean of the individual differences between the measurements at terminal
and baseline examination. For other details see legend to Figure 1. Because
the glutamate uptake was previously shown to depend strongly on the
arterial glutamate concentration, we indicated in Figure 2 the changes in the
‘relative glutamate uptake’ as defined by the ratio of glutamate uptake/arterial
glutamate level (see Hack et al, 1996b)
Figure 3 Effect of L-carnitine on the intramuscular GSH and glutamate
levels and plasma glutamate concentrations of tumour-bearing mice. The
bars show the results (arithmetic means ± s.e.m.) from normal mice, tumour-
bearing mice and tumour-bearing mice treated with a dose of 1 mg L-
carnitine i.p. per day. The data show the means ± s.e.m. from 24 separate
muscle preparations each (i.e. two separate experiments with six animals per
group and two separate muscle preparations per mouse)C57/BL6 mice bearing the MCA 105 fibrosarcoma (Hack et al,
1996a) received daily intraperitoneal injections of graded doses of
L-carnitine (i.e. 0.0, 0.04, 0.2, 1, or 5 mg per day) on 7 consecutive
days starting 2 weeks after tumour inoculation. Mice were sacri-
ficed 1 day after the last injection of L-carnitine. The results
confirmed the earlier findings that intramuscular GSH and gluta-
mate concentrations in the tumour-bearing mice are strongly
decreased and plasma glutamate concentrations strongly increased
in comparison with non-tumour-bearing controls. These changes
were at least partly reversed by daily injections of 1 mg L-carnitine
(Figure 3). Lower doses yielded no significant changes, whereas
5 mg day–1 (approximately 250 mg kg–1 day–1) reversed the
increase in intramuscular glutamate and glutathione that was seen
with 1 mg day–1 (not shown). The changes in the blood plasma
were also reflected in corresponding changes in the liver
(Figure 4). These changes were essentially the mirror image of the
changes in the skeletal muscle tissue. However, L-carnitine
induced no consistent changes in the levels of glutamine or BCAA
in the plasma or skeletal muscle tissue of the tumour-bearing mice
(data not shown).
DISCUSSION
The results from the tumour-bearing mice confirm the hypothesis
that L-carnitine may be an effective treatment to reconstitute the
abnormally low intramuscular GSH levels in malignancies. The
concomitant increase in the intramuscular glutamate and the
decrease in the plasma glutamate level in carnitine-treated mice
support the interpretation that the increase in muscular GSH may
be mediated by an increase in the net glutamate transport into the
skeletal muscle tissue. In agreement with these findings, carnitine
treatment caused also a significant decrease in plasma glutamate
levels in our randomized study on cancer patients, although the
relative net glutamate uptake in the lower extremities of the cancer
patients was only marginally increased by this treatment. To
explain this apparent discrepancy we propose tentatively that
ingestion of L-carnitine may enhance the glutamate transport only
transiently. This effect may not be detectable any more in the post-
absorptive period, when the decrease in the plasma glutamate
level, i.e. the putative consequence of the temporary increase in
glutamate uptake, is still demonstrable. This interpretation remains
to be tested. The effect of L-carnitine on the release of BCAA
(Figure 2), finally, is still poorly understood and requires further
investigation.
Elevated hepatic GSH levels in tumour-bearing mice (Figure 4)
may appear as a compensatory antioxidant response and may seem
advantageous at face value. However, earlier investigations on this
tumour model have shown that the increase in hepatic GSH is
associated with an increased release of GSH into the bile and may
therefore lead ultimately to a loss of cysteine (Hack et al, 1996a).
It is tempting to assume that the increased hepatic glutamate and
GSH levels may result indirectly from the decreased glutamate
uptake by the skeletal muscle tissue and the corresponding
increase in plasma glutamate levels. However, it cannot be
formally excluded that biochemical changes in the liver itself may
contribute to the systemic increase in glutamate levels.
Taken together, the effects of L-carnitine on the intramuscular
GSH levels is potentially useful in clinical therapy. This thera-
peutic potential and especially the effects of longer treatment
periods may deserve further investigation. However, high doses of
L-carnitine, i.e. 250 mg kg–1 day–1, may be disadvantageous,
because this dose was found to cause a substantial decrease in
intramuscular glutamate and GSH levels in the skeletal muscle
tissue of tumour-bearing mice.
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